TransMedics publishes investor presentation on Organ Care System platform, national procurement and transplant logistics network

TransMedics Group

TransMedics Group

TMDX

0.00
  • TransMedics outlined plans to scale its Organ Care System platform toward 20,000+ annual OCS transplants, supported by new programs and international expansion.
  • FY26 revenue guidance set at USD 727 million to USD 757 million, implying 20% to 25% growth.
  • Cash balance of USD 461.7 million as of March 31, 2026.
  • U.S. infrastructure highlighted at 19 clinical hubs, 22 dedicated planes, 50+ procurement surgeons.
  • Registry utilization rates cited at 96% for lungs, 97% for hearts, 98% for livers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transmedics Group Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.